切换至 "中华医学电子期刊资源库"
高级检索
中华神经创伤外科电子杂志

中华神经创伤外科电子杂志 ›› 2021, Vol. 07 ›› Issue (05) : 261 -265. doi: 10.3877/cma.j.issn.2095-9141.2021.05.002

基础研究

NHE1抑制剂改善胶质母细胞瘤细胞对替莫唑胺耐药性的研究
孙明阳1, 刘艳坤2, 陈思1, 李玉凤2, 李玉辉1,†()   
  1. 1. 063001　唐山市人民医院神经外科
    2. 063001　唐山市人民医院肿瘤研究所
  • 收稿日期:2021-06-03 出版日期:2021-10-15
  • 通信作者: 李玉辉
  • 基金资助:
    唐山市科技创新团队培养计划项目基金(18130203B); 河北省分子肿瘤学重点实验室(SZX2020042)

NHE1 inhibitor improves temozolomide-resistance of human glioblastoma cells

Mingyang Sun1, Yankun Liu2, Si Chen1, Yufeng Li2, Yuhui Li1,†()   

  1. 1. Department of Neurosurgery, Tangshan People’s Hospital, Tangshan 063001, China
    2. Cancer Institute, Tangshan People’s Hospital, Tangshan 063001, China
  • Received:2021-06-03 Published:2021-10-15
  • Corresponding author: Yuhui Li
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

孙明阳, 刘艳坤, 陈思, 李玉凤, 李玉辉. NHE1抑制剂改善胶质母细胞瘤细胞对替莫唑胺耐药性的研究[J]. 中华神经创伤外科电子杂志, 2021, 07(05): 261-265.

Mingyang Sun, Yankun Liu, Si Chen, Yufeng Li, Yuhui Li. NHE1 inhibitor improves temozolomide-resistance of human glioblastoma cells[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2021, 07(05): 261-265.

目的

分析Na+/H+交换蛋白1（NHE1）抑制剂Cariporide改善对替莫唑胺（TMZ）耐药的胶质母细胞瘤（GBM）细胞耐药性的作用。

方法

采用本课题组前期建立的对TMZ耐药（TR）细胞系U87/TR和U251/TR，Cariporide分别处理各组细胞，乙酰甲酯化的2’，7’-双(2-羧乙基)-5(6)-羧荧光素荧光探针分析NHE1的活性，CCK-8法检测细胞增殖活性，计算细胞存活率。

结果

CCK-8法证实U87/TR和U251/TR对TMZ耐药。U87/TR和U251/TR细胞内NHE1活性、细胞存活率均分别显著高于亲本U87和U251细胞，差异均具有统计学意义（P<0.05）；Cariporide处理的U87/TR和U251/TR细胞内NHE1活性显著高于亲本U87和U251细胞，但分别显著低于未添加Cariporide的U87/TR和U251/TR细胞，差异均具有统计学意义（P<0.05）；在325 μmol/L TMZ培养的条件下，Cariporide处理的U87/TR和U251/TR细胞存活率显著高于亲本U87和U251细胞，但分别显著低于未添加Cariporide的U87/TR和U251/TR细胞，差异均具有统计学意义（P<0.05）。

结论

采用Cariporide阻断NHE1活性可部分改善GBM细胞对TMZ的耐药性。

关键词: 胶质母细胞瘤, 替莫唑胺, 耐药, NHE1抑制剂
Objective

To analyze the effect of Na+/H+ exchanger 1 (NHE1) inhibitor Cariporide on improving temozolomide (TMZ)-resistance of human glioblastoma (GBM) cells.

Methods

Each group of cells was treated with TMZ resistant (TR) cell lines U87/TR and U251/TR, Cariporide which established in the early stage of this research group. The NHE1 activity was detected with acetoxymethyl ester of 2’,7’-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein fluorescent probe. The cell viability was analyzed by CCK-8 and the cell survival rate was calculated.

Results

The TMZ-resistances of U87/TR and U251/TR were confirmed by CCK-8 method. The NHE1 activity and cell survival rate of U87/TR and U251/TR were significantly higher than those of parental U87 and U251 cells, respectively (P<0.05). The NHE1 activities of Cariporide-treated U87/TR and U251/TR cells were still significantly higher than their parental cells, they were significantly lower than U87/TR and U251/TR cells without Cariporide, respectively (P<0.05). Under the conditions cultured at 325 μmol/L TMZ, the cell survival rate of Cariporide-treated U87/TR and U251/TR cells remained significantly higher than their parental cells, they were significantly lower than U87/TR and U251/TR cells without Cariporide, respectively (P<0.05).

Conclusion

Inhibition of NHE1 activity with Cariporide could partially improve the TMZ-resistance of GBM cells.

Key words: Glioblastoma, Temozolomide, Drug resistance, NHE1 inhibitor
图1 CCK-8分析各组细胞在325 μmol/L TMZ中的存活率
图2 BCECF-AM荧光探针分析各组细胞内FIR值
图3 CCK-8分析各组细胞在325 μmol/L TMZ中的细胞存活率
[1]
Lee SY. Temozolomide resistance in glioblastoma multiforme[J]. Genes Dis, 2016, 3(3): 198-210.
[2]
Jiapaer S, Furuta T, Tanaka S, et al. Potential strategies overcoming the temozolomide resistance for glioblastoma[J]. Neurol Med Chir (Tokyo), 2018, 58(10): 405-421.
[3]
Guan X, Luo L, Begum G, et al. Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas[J]. J Exp Clin Cancer Res, 2018, 37(1): 255.
[4]
李玉辉,赵喜庆,陈思,等.阻断NHE1抑制人胶质母细胞瘤细胞增殖和侵袭的研究[J].中华神经创伤外科电子杂志, 2020, 6(1): 39-43.
[5]
Chen W, Xu XK, Li JL, et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression[J]. Oncotarget, 2017, 8(14): 22783-22799.
[6]
Gerson SL. Clinical relevance of MGMT in the treatment of cancer[J]. J Clin Oncol, 2002, 20(9): 2388-2399.
[7]
石文健,赵喜庆,张欢,等.沉默NHE1抑制胶质母细胞瘤细胞的迁移和侵袭能力[J].基因组学与应用生物学, 2017, 36(12): 4984-4991.
[8]
Mansoori B, Mohammadi A, Davudian S, et al. The different mechanisms of cancer drug resistance: a brief review[J]. Adv Pharm Bull, 2017, 7(3): 339-348.
[9]
黄柯,刘王波,刘涛.钠氢交换体1调节肿瘤微环境对肿瘤细胞的影响[J].临床外科杂志, 2019, 27(9): 825-827.
[10]
Brisson L, Reshkin SJ, Goré J, et al. pH regulators in invadosomal functioning: proton delivery for matrix tasting[J]. Eur J Cell Biol, 2012, 91(11-12): 847-860.
[11]
Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method[J]. Cancer Res, 2010, 70(2): 440-446.
[12]
Cardone RA, Greco MR, Zeeberg K, et al. A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy[J]. Neoplasia, 2015, 17(2): 155-166.
[13]
Wang J, Zhou Y, Ma L, et al. CIAPIN1 targeted NHE1 and ERK1/2 to suppress NSCLC cells’ metastasis and predicted good prognosis in NSCLC patients receiving pulmonectomy[J]. Oxid Med Cell Longev, 2019, 2019: 1970818.
[1] 王雪菲, 海琳悦, 李立方, 肖春花. Luminal A型乳腺癌的内分泌治疗与化疗[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 294-300.
[2] 涂家金, 廖武强, 刘金晶, 涂志鹏, 毛远桂. 严重烧伤患者鲍曼不动杆菌血流感染的危险因素及预后分析[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 491-497.
[3] 李维, 莫俊俏. 儿童呼吸道耐药流感嗜血杆菌基因型鉴定及耐药分析对抗菌药物治疗选择的意义[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 315-323.
[4] 张小曼, 马筱秋, 许正锯, 张纯瑜, 何彩婷. 乙型肝炎病毒逆转录酶区耐药突变对血清乙型肝炎病毒表面抗原水平的影响[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 324-332.
[5] 张海金, 王增国, 蔡慧君, 赵炳彤. 2020至2022年西安市儿童医院新生儿细菌感染分布及耐药监测分析[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(04): 222-229.
[6] 曹长青, 郭新艳, 高源, 张存, 唐海利, 樊东, 杨小军, 张松, 赵华栋. 肿瘤微环境参与介导HER2阳性乳腺癌曲妥珠单抗耐药的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 90-95.
[7] 刘付有欢, 吴秀芹, 邓翠婷, 苏青. 基于模型的西妥昔单抗治疗胃癌细胞系的反应和耐药因素分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 385-388.
[8] 王晓丹, 王媛, 崔向宇, 任晓磊. 上尿路结石内镜手术后尿源性脓毒血症病原菌耐药及死亡高危因素分析[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 611-615.
[9] 王庆, 张红联, 吴志勇. COPD合并多重耐药菌肺部感染预后危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 557-559.
[10] 李咏生, 孙建国, 李梦侠, 重庆肺癌精准治疗协作组(CPLOG). 第三代EGFR-TKI耐药后诊疗策略专家共识[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 145-155.
[11] 张燕珍, 王锡携, 文小兰. 血清巨噬细胞迁移抑制因子对活动性肺结核分诊检测的意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 200-202.
[12] 王甜甜, 温媛, 李振, 叶美红, 郭影, 马双. 和厚朴酚调控Nrf2/ARE通路对胃癌细胞的顺铂化疗敏感性的影响[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 202-209.
[13] 李静静, 翟蕾, 赵海平, 郑波. 多囊肾合并囊肿的多重耐药菌感染一例并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(08): 920-923.
[14] 李琪, 黄钟莹, 袁平, 关振鹏. 基于某三级医院的ICU多重耐药菌医院感染影响因素的分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 777-782.
[15] 林舒楠, 党文强, 钟天, 梁斯欣, 张磊, 唐晓华, 袁文常. 2017—2021年广东地区基层医疗机构金黄色葡萄球菌临床分离株耐药谱分析[J]. 中华临床实验室管理电子杂志, 2023, 11(03): 139-144,150.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号